Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation

Ponatinib is a multi-targeted third generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukemia (CML) patients harboring the Abelson (Abl)-breakpoint cluster region (Bcr) T315I mutation. In spite of having superb clinical efficacy, ponatinib triggers severe vascular...

Descripción completa

Detalles Bibliográficos
Autores principales: Paez-Mayorga, Jesus, Chen, Andrew L., Kotla, Sivareddy, Tao, Yunting, Abe, Rei J., He, Emma D., Danysh, Brian P., Hofmann, Marie-Claude C., Le, Nhat-Tu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135907/
https://www.ncbi.nlm.nih.gov/pubmed/30238007
http://dx.doi.org/10.3389/fcvm.2018.00125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6135907/
https://www.ncbi.nlm.nih.gov/pubmed/30238007
http://dx.doi.org/10.3389/fcvm.2018.00125

Ejemplares similares